^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CLDN18.2 overexpression

i
Entrez ID:
Related biomarkers:
1m
Pan-cancer analysis of CLDN18.2 shed new insights on the targeted therapy of upper gastrointestinal tract cancers. (PubMed, Front Pharmacol)
Additionally, low CLDN18.2 expression was linked to favorable prognosis. Our study reveals the potential value of CLDN18.2 for tumor prognosis and targeted therapy in various cancers, especially upper gastrointestinal tract cancers.
Journal • Pan tumor
|
CLDN18 (Claudin 18) • CD4 (CD4 Molecule)
|
CLDN18.2 expression • CLDN18.2 overexpression • CLDN18.2 underexpression
4ms
Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer. (PubMed, Cell Death Discov)
Inhibiting autophagy by autophagy inhibitor LY294002 remarkably enhanced αCLDN18.2-MMAE-induced cytotoxicity and caspase-mediated apoptosis, indicating the cytoprotective role of autophagy in CLDN18.2-directed ADC-treated gastric cancer cells...Besides, the Akt/mTOR pathway inactivation was demonstrated to be implicated in the autophagy initiation in αCLDN18.2-MMAE-treated gastric cancer cells. In conclusion, our study highlighted a groundbreaking investigation into the mechanism of the CLDN18.2-directed ADC, focusing on the crucial role of autophagy, providing a novel insight to treat gastric cancer by the combination of CLDN18.2-directed ADC and autophagy inhibitor.
Journal • PARP Biomarker
|
CLDN18 (Claudin 18) • CASP9 (Caspase 9)
|
CLDN18.2 positive • CLDN18.2 overexpression • CLDN1 overexpression
|
LY294002
9ms
Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management. (PubMed, J Natl Compr Canc Netw)
The activity of perioperative chemotherapy-free immune checkpoint regimens in patients with nonmetastatic dMMR/MSI-H cancer is highly promising and underscores the need to identify this unique subgroup. We recommend MMR/MSI testing for all patients with GEA at diagnosis, and review the key rationale and clinical management implications for patient with dMMR/MSI-H tumors across disease stages.
Review • Journal • Mismatch repair • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • CLDN18 (Claudin 18)
|
PD-L1 expression • MSI-H/dMMR • HER-2 overexpression • CLDN18.2 overexpression • CLDN1 overexpression
10ms
Advances in targeted therapy for gastric cancer based on tumor driver genes. (PubMed, Zhejiang Da Xue Xue Bao Yi Xue Ban)
Among them, trastuzumab, as the first targeted drug for gastric cancer, effectively inhibits the proliferation and metastasis of tumor cells by targeting overexpressed HER2, and has become the standard treatment for HER2-positive gastric cancer patients. Ramucirumab, on the other hand, inhibits tumor angiogenesis by targeting VEGFR2 and has been used as second-line therapy for advanced gastric cancer patients. In addition, bemarituzumab targets overexpressed FGFR2, while zolbetuximab targets overexpressed CLDN18.2, significantly extending progression-free survival and overall survival in patients with gastric cancer in clinical trials. This article reviews the roles of tumor driver genes in the progression of gastric cancer; and the treatment strategies for gastric cancer based on targeting HER2, VEGF, FGFR2, CLDN18.2, MET and other tumor driver genes, aiming to provide reference for clinical application of targeted therapy for gastric cancer.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • CLDN18 (Claudin 18) • KDR (Kinase insert domain receptor)
|
HER-2 positive • HER-2 overexpression • CLDN18.2 expression • FGFR2 overexpression • CLDN18.2 overexpression • CLDN1 overexpression
|
Herceptin (trastuzumab) • Cyramza (ramucirumab) • Vyloy (zolbetuximab-clzb) • bemarituzumab (AMG 552)
12ms
Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression. (PubMed, Cell Commun Signal)
Our findings illuminated the role of the CLDN18.2-mediated interaction between cancer cells and CAFs in promoting gastric cancer progression and embolism, thereby providing insight into potential therapeutic avenues for CLDN18.2 positive cancers. Video Abstract.
Journal
|
CLDN18 (Claudin 18) • S100A4 (S100 calcium binding protein A4)
|
CLDN18.2 expression • CLDN18.2 positive • CLDN18.2 overexpression • CLDN18.2 underexpression
1year
Screening, Construction, and Preliminary Evaluation of CLDN18.2-Specific Peptides for Noninvasive Molecular Imaging. (PubMed, ACS Pharmacol Transl Sci)
The Ga-DOTA-T37 probe exhibits good in vitro properties and high stability as a hydrophilic probe; it has high biological safety, and positron emission tomography/computed tomography (PET/CT) studies have shown that it can specifically target CLDN18.2 protein and CLDN18.2-positive tumors in mice. Ga-DOTA-T37 demonstrated the superiority and feasibility of using a CLDN18.2-specific probe in PCT/CT imaging, which deserves further development and exploitation.
Journal
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression • CLDN18.2 positive • CLDN18.2 overexpression
1year
[Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models. (PubMed, Eur J Nucl Med Mol Imaging)
In preclinical studies, [Lu]Lu-TST001 demonstrated significant antitumor efficacy with acceptable toxicity. It exhibits strong potential for clinical translation, providing a new promising treatment option for CLDN18.2-overexpressing tumors, including GC.
Preclinical • Journal
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression • CLDN18.2 positive • CLDN18.2 overexpression • CLDN1 overexpression
|
osemitamab (TST001)
1year
Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer. (PubMed, Sci Rep)
In conclusion, claudin 18.2 was overexpressed in almost half of resectable gastric cancer patients. Claudin 18.2 overexpression was associated with some clinicopathological characteristics, but was not an independent prognostic factor in a localized setting.
Retrospective data • Journal
|
CLDN18 (Claudin 18)
|
CLDN18.2 overexpression • CLDN1 overexpression
1year
New developments and standard of care in the management of advanced gastric cancer. (PubMed, Clin Res Hepatol Gastroenterol)
More recently, two monoclonal antibodies have demonstrated their efficacy in combination with oxaliplatin-based first-line chemotherapy, nivolumab (anti-PD1) for PD-L1 CPS ≥5 tumors, and zolbetuximab for tumors overexpressing Claudin 18.2. Recent years have seen the emergence of new drugs that have improved patient survival, such as trastuzumab in first-line for HER2-positive tumors, ramucirumab alone or in combination with paclitaxel in second-line, and trifluridine-tipiracil beyond the second-line treatment. Advanced gastric adenocarcinoma is a common disease with a poor prognosis whose treatment has for decades been based on cytotoxic chemotherapy, including platinum salts in first-line, and taxane or irinotecan in second or later line. In addition, regorafenib has been also showed effective in phase 3 trial for heavily pretreated patients. Based on phase 2 studies, trastuzumab-deruxtecan was approved in 2022 by the EMA for HER2-positive pretreated patients. This agent is currently evaluated in phase 3 study (DESTINY-Gastric04 trial), as are several other anti-HER2 (zanidatamab, margetuximab, tucatinib), immune checkpoint inhibitors, or targeted therapies (anti-FGFR2b).
Review • Journal • Metastases
|
CLDN18 (Claudin 18)
|
HER-2 positive • CLDN18.2 overexpression • CLDN1 overexpression
|
Opdivo (nivolumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • Stivarga (regorafenib) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • Tukysa (tucatinib) • Margenza (margetuximab-cmkb) • Lonsurf (trifluridine/tipiracil) • Vyloy (zolbetuximab-clzb) • Ziihera (zanidatamab-hrii)
over1year
Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression. (PubMed, J Clin Med)
CLDN18 is frequently expressed in PDAC, and high CLDN18-expressing PDACs showed some different clinicopathologic characteristics. High CLDN18 expression was not associated with prognosis in patients with surgically resected PDAC.
Journal
|
CLDN18 (Claudin 18)
|
CLDN18.2 overexpression
|
Vyloy (zolbetuximab-clzb)
over1year
CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer. (PubMed, Gastroenterology)
Our data suggest that BiTE molecule treatment converts Treg function from immunosuppressive to immune enhancing, leading to antitumor activity in immunogenically "cold" tumors.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
CLDN18 (Claudin 18)
|
CLDN18.2 overexpression
|
gresonitamab (AMG 910)
over1year
Impact of HER2 and PD-L1 co-expression in Claudin18.2 positive resectable gastroesophageal cancers (ESMO 2023)
Conclusions Biomarker co-expression may be frequent in the CDLN18.2+ve subset, and CLDN18.2+ve/HER2+ve may reveal a genomically more complex subgroup. Evaluation in larger datasets is required to understand its biological significance and potential therapeutic implications.
Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CLDN18 (Claudin 18)
|
PD-L1 expression • HER-2 overexpression • HER-2 expression • CLDN18.2 overexpression • CLDN1 overexpression
over1year
First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-Cohort C (ESMO 2023)
Encouraging anti-tumor activities have been observed regardless of the CLDN18.2 expression levels, including expression as low as ≥10% tumor cells staining ≥1+, <40% tumor cells staining <2+ or 3+. Overall survival data will be presented.
Clinical • Metastases
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression • CLDN18.2 positive • CLDN18.2 overexpression • CLDN1 positive
|
capecitabine • oxaliplatin • osemitamab (TST001)
over1year
First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection. (PubMed, Eur J Nucl Med Mol Imaging)
I-18B10(10L) was successfully prepared and exhibited a high binding affinity and CLDN18.2 specificity in preclinical studies. As an FiH CLDN18.2 PET tracer, I-18B10(10L) was shown to be safe with acceptable dosimetry and to clearly reveal most lesions overexpressing CLDN18.2.
P1 data • Journal
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression • CLDN18.2 overexpression
over1year
Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors. (PubMed, J Pharm Anal)
A dosimetry estimation study showed that the effective dose of &lsqb;Zr]Zr-DFO-TST001 was 0.0705 mSv/MBq, which is within the range of acceptable doses for nuclear medicine research. Taken together, these results suggest that Good Manufacturing Practices produced by this immuno-positron emission tomography probe can detect CLDN18.2-overexpressing tumors.
Journal
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression • CLDN18.2 positive • CLDN18.2 overexpression
|
osemitamab (TST001)
over1year
Osemitamab plus capecitabine and oxaliplatin (CAPOX) as the first-line treatment of advanced G/GEJ cancer – updated efficacy data per claudin 18.2 expression level from study TranStar102/TST001-1002-cohort C (ESMO-GI 2023)
Funding: Suzhou Transcenta Therapeutics Co., Ltd.Background: Claudin18.2 antibody plus chemotherapy is a clinically validated approach for patients with high CLDN18.2 expressing tumors, which has been proven by zolbetuximab. Osemitamab plus CAPOX as first-line treatment for patients with G/GEJ cancer demonstrated good safety and tolerability. Encouraging anti-tumor activities have been observed regardless of the CLDN18.2 expression levels above 10%, 1+ per central LDT assay.
Clinical • Metastases
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression • CLDN18.2 overexpression
|
capecitabine • oxaliplatin • Vyloy (zolbetuximab-clzb) • osemitamab (TST001)
over1year
CLDN18.2 expression in resectable gastroesophageal cancers: Associated clinical and molecular signatures and impact of neoadjuvant chemotherapy on intratumor heterogeneity (ESMO-GI 2023)
Zolbetuximab, an anti-CLDN18.2 monoclonal antibody, plus chemotherapy has outperformed chemotherapy alone in a global biomarker-informed phase 3 study in the front-line setting, and interest is growing in exploring CLDN18.2-targeted agents in the perioperative space... CLDN18.2+ve and CLDN18.2-ve tumours had similar genomic and immune signatures. However, nCT substantially contributes to CLDN18.2 spatial and temporal heterogeneity. Larger cohorts will need to confirm these findings, which could have implications for therapy.
Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CLDN18 (Claudin 18)
|
PD-L1 expression • CLDN18.2 expression • CLDN18.2 overexpression
|
Vyloy (zolbetuximab-clzb)
over1year
Jianpi Yangzheng decoction suppresses gastric cancer progression via modulating the miR-448/CLDN18.2 mediated YAP/TAZ signaling. (PubMed, J Ethnopharmacol)
JPYZ has an inhibitory effect on GC growth and metastasis partly by elevating CLDN18.2 abundance in GC cells, indicating more patients may benefit from combination therapy of JPYZ and the upcoming CLDN18.2 target agents.
Journal
|
CLDN18 (Claudin 18)
|
CLDN18.2 overexpression
almost2years
The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes. (PubMed, Medicine (Baltimore))
HER-2 expression is low and CLDN18.2 expression is high in patients with PDAC. HER-2 expression is not related to overall survival but CLDN18.2 is related and may be used as a prognostic marker in patients with PDAC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
|
HER-2 expression • CLDN18.2 expression • CLDN18.2 overexpression
2years
Comparative efficacy and tolerability of targeted and immunotherapy combined with chemotherapy as first-line treatment for advanced gastric cancer: a Bayesian network meta-analysis. (PubMed, Sci Rep)
In average group, no regimen showed significant improvements in overall survival (OS) and progression free survival (PFS), while pembrolizumab and nivolumab combined with chemotherapy were ranked first and second respectively without an obvious safety difference...The top three regimens were zolbetuximab-chemotherapy, trastuzumab plus pertuzuma-chemotherapy and nivolumab-chemotherapy respectively, with no significant safety risk. For average patients, immune checkpoint inhibitor PD-1 plus chemotherapy will be the promising regimen. For patients with overexpression of CLDN18.2, zolbetuximab combined with chemotherapy comes with greater survival benefits, while for patients who have PD-L1 expression with no HER-2 or CLDN18.2 positivity, additional immune checkpoint inhibitor of PD-1 will be a good considered option.
Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
|
PD-L1 expression • HER-2 expression • CLDN18.2 expression • CLDN18.2 overexpression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Vyloy (zolbetuximab-clzb)
2years
Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study. (ASCO-GI 2023)
Under the expanded protocol amendment, 95 of ~140 sites in North America, Latin America, Europe, and Asia Pacific were activated. Clinical trial information: NCT03816163.
Clinical • P2 data • Metastases
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression • CLDN18.2 positive • CLDN18.2 overexpression
|
gemcitabine • albumin-bound paclitaxel • Vyloy (zolbetuximab-clzb)
2years
The impact of claudin-18.2 expression in patients with advanced gastric cancer treated with nivolumab. (ASCO-GI 2023)
With CLDN18.2 high, CPS≥1 was associated with longer survival in AGC treated with NIVO.
Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CLDN18 (Claudin 18) • CD8 (cluster of differentiation 8)
|
CLDN18.2 expression • CLDN18.2 overexpression • CD8 negative
|
Opdivo (nivolumab)
2years
Anti-CLDN18.2 antibody ZL-1211 enhances anti-tumor activities in combination with chemotherapy in gastric cancer models (SITC 2022)
Chemotherapy, such as gemcitabine, increased CLDN18.2 mRNA and protein expression levels in cancer cells and sensitized tumor cells to ZL-1211-mediated ADCC. Furthermore, ZL-1211 in combination with SoC chemotherapies, oxaliplatin + capecitabine (CAPOX), enhanced anti-tumor efficacy in SNU601 gastric cancer xenograft model...Conclusions These data provide rationale to combine ZL-1211 with SoC chemotherapy in gastric cancer. Currently, a phase I dose escalation study is underway to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of ZL-1211 in patients with advanced solid tumors ( NCT05065710 ).
Preclinical • Combination therapy
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression • CLDN18.2 overexpression
|
gemcitabine • capecitabine • oxaliplatin • ZL-1211
over2years
Preclinical activity for TPX-4589 (LM-302), an antibody-drug conjugate targeting tight junction protein CLDN18.2 in solid tumors (AACR-NCI-EORTC 2022)
In a CLDN18.2-high patient-derived xenograft (PDX) PC tumor model, increasing doses of TPX-4589 demonstrated superior tumor growth inhibition compared to gemcitabine and LM-102, a compound with identical anti-CLDN18.2 mAb component as LM-302, and similar efficacy to LM-102 + gemcitabine in combination. TPX-4589, a novel CLDN18.2-targeting ADC, showed potent inhibitory effects on tumor cell proliferation in vitro and reduced tumor volume in both high- and low-expressing CDLN18.2 tumor models, with superior internalization and efficacy to zolbetuximab in a GC tumor model. These data suggest that TPX-4589 is a promising therapeutic candidate that warrants further investigation in clinical studies.
Preclinical
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression • CLDN18.2 positive • CLDN18.2 overexpression • CLDN18.2 underexpression
|
gemcitabine • Vyloy (zolbetuximab-clzb) • tecotabart vedotin (LM-302)
over2years
Development and comparison of three Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study. (PubMed, Eur J Nucl Med Mol Imaging)
Both anti-CLDN18.2 VHH-ABD and anti-CLDN18.2 VHH-Fc can be efficiently and stably radiolabeled with Zr for noninvasive imaging and quantification of CLDN18.2 expression in gastric cancer, of which Zr-anti-CLDN18.2 VHH-ABD seems to be the optimal choice balancing tumor uptake and liver background. They can provide essential information to select patients who are likely to benefit from CLDN18.2-targeted treatment.
Preclinical • Journal
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression • CLDN18.2 overexpression
over2years
A phase I study of TST001, a high affinity humanized anti-CLDN18.2 monoclonal antibody, in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment of advanced G/GEJ cancer. (ASCO 2022)
TST001 in combination with CAPOX in first line gastric cancer patients is safe and encouraging anti-tumor activities have been observed. Additional data from the 6 mg/kg dose expansion cohort will be updated at the meeting.
Clinical • P1 data • Combination therapy
|
CLDN18 (Claudin 18) • CLDN8 (Claudin 8)
|
CLDN18.2 expression • CLDN18.2 overexpression
|
capecitabine • oxaliplatin • osemitamab (TST001)
over2years
Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study. (ASCO 2022)
Data will be presented using descriptive statistics for continuous endpoints and frequency and percentage for categorical endpoints. At original protocol enrollment completion (October 2021), 84 sites were actively recruiting; sites are currently reopening for screening/enrollment pending protocol amendment approval.
Clinical • P2 data
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression • CLDN18.2 overexpression
|
gemcitabine • albumin-bound paclitaxel • Vyloy (zolbetuximab-clzb)
almost3years
Evaluation of the efficacy of ADC in vitro and in vivo (AACR 2022)
In terms of in vivo ADCs assessment, our abundant CDX and PDX resource facilitates the process of in vivo ADCs evaluation, and we have already assess the efficacy of ADC or the combination treatment of ADC and other anti-tumor drugs in several animal models. Last but not the least, our high-throughput MSD (MESO QuickPlex) and Luminex (Bio-PlexTM 200 system) platform boosts the evaluation of ADCs safety by measuring the extent of cytokine release syndrome.
Preclinical
|
CLDN18 (Claudin 18) • MIA (MIA SH3 Domain Containing) • CLDN8 (Claudin 8)
|
CLDN18.2 overexpression
almost3years
PT886, an anti-claudin18.2/anti-CD47 bispecific antibody constructed with the PACbodyTM and SPECpairTM technology platforms, exhibits robust anti-tumor activity in a pancreatic cancer xenograft model (AACR 2022)
These data support the proof of concept of the PACbody™ and SPECpair™ technology platforms and demonstrate the unique profile of our anti-CD47 arm that’s suitable for the bispecific antibody approach. PT886 is a first-in-class anti-CLDN18.2/anti-CD47 bispecific antibody with native IgG-like structure and phase 1 clinical trial is planned for the first quarter of 2022.
Preclinical
|
CLDN18 (Claudin 18) • CD47 (CD47 Molecule) • CLDN8 (Claudin 8) • SIRPA (Signal Regulatory Protein Alpha)
|
CLDN18.2 expression • CLDN18.2 overexpression
|
PT886
almost3years
ATG-022, an antibody-drug conjugate targeting Claudin 18.2, demonstrated potent in vivo efficacy in gastric cancer patient-derived xenografts (AACR 2022)
The monoclonal antibody targeting CLDN18.2 (IMAB362) has demonstrated promising clinical benefit in combination with chemotherapies for gastric cancer patients. ATG-022 demonstrated potent in vitro and in vivo antitumor effects, with in vivo efficacy observed in CLDN18.2-low expression PDX models, suggesting a promising therapeutic strategy for gastric cancer patients with a broad range of CLDN18.2 expression levels.
Preclinical
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression • CLDN18.2 positive • CLDN18.2 overexpression • CLDN18.2 underexpression
|
Vyloy (zolbetuximab-clzb) • ATG-022
over3years
[VIRTUAL] Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2. (ASCO 2021)
Funding: Astellas Pharma Clinical Trial Registry Number: NCT03505320 Background: One accepted treatment for patients (pts) with advanced HER2-negative G/GEJ is mFOLFOX6 (5-FU, folinic acid, oxaliplatin)...Phase 2 results (NCT01630083, FAST) showed prolonged survival with zolbetuximab+EOX (epirubicin, oxaliplatin, capecitabine) vs EOX in G/GEJ... Results suggest promising antitumor activity with zolbetuximab+mFOLFOX6 in metastatic or locally advanced G/GEJ . The safety profile was manageable and no new safety signals were identified.
P2 data
|
HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
|
HER-2 negative • CLDN18.2 expression • CLDN18.2 overexpression
|
5-fluorouracil • capecitabine • oxaliplatin • epirubicin • leucovorin calcium • Vyloy (zolbetuximab-clzb)